- ￥656 - 3249
- Solarbio
- 北京
- IG2370
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
GDC-0623
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
1168091-68-6
- 规格：
25mg/10mg/1mg/5mg/2mg
| 规格： | 25mg | 产品价格： | ￥3249.0 |
|---|---|---|---|
| 规格： | 10mg | 产品价格： | ￥2238.0 |
| 规格： | 1mg | 产品价格： | ￥656.0 |
| 规格： | 5mg | 产品价格： | ￥1390.0 |
| 规格： | 2mg | 产品价格： | ￥940.0 |
| 基本信息 | |
| CAS | No.1168091-68-6 |
| 英文名称 | GDC-0623 |
| 别名 | RG-7421 |
| 分子式 | C16H14FIN4O3 |
| 分子量 | 456.21 |
| 溶解性 | Soluble in DMSO ≥5mg/mL |
| 纯度 | ≥98% |
| 外观(性状) | Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| EC | EINECS 604-604-1 |
| MDL | MFCD25976760 |
| SMILES | FC(C=C(I)C=C1)=C1NC2=C(C(NOCCO)=O)C=CC3=CN=CN23 |
| 靶点 | MEK |
| 通路 | MAPK |
| 背景说明 | GDC-0623是一种新型的,有效的,选择性的,ATP竞争性的MEK1抑制剂。MEK是RAS/RAF/MEK/ERK信号通路中调节细胞生长的关键组成部分,该通路的组成型激活与许多癌症有关。 |
| 生物活性 | GDC-0623 (RG 7421) is a potent， ATP-uncompetitive inhibitor of MEK1 (Ki=0.13 nM， +ATP)， and displays 6-fold weaker potency against HCT116 (KRAS (G13D)， EC50=42 nM) versus A375 (BRAFV600E， EC50=7 nM).[1-2] |
| In Vitro | GDC-0623 (RG 7421) and G-573 are able to prevent MEK phosphorylation by CRAF in vitro， and able to block MEK phosphorylation by BRAF(V600E)[1]. GDC-0623 (RG 7421) is potent， ATP-uncompetitive inhibitors of MEK1 but shows distinct shifts in cellular activity compared with the other two inhibitors， only 6-fold half-maximum effective concentration (EC50) decreases[2]. |
| 细胞实验 | GDC-0623 (RG 7421) (40 mg/kg， p.o.) shows percent tumour growth inhibition (%TGI) in MiaPaCa-2 xenograft model. GDC-0623 (RG 7421) and G-573 show superior antitumour activity compared to GDC-0623 (RG 7421) in all three KRAS models[1]. |
| 细胞实验 | Flag-MEK1 mutants， S212P and S212A， are generated using the QuickChange site directed mutagenesis kit. Mammalian expression vectors for N-terminal Flag tagged MEK-1 are expressed in HCT116 cells. 1.8×106 HCT116 cells are plated in 10 cm plate and transfected on the following day with 17 μg of expression constructs using lipofectamine 2000. After 48 hours cells are treated with inhibitors for the indicated times， harvested and lysed in 100 μL cell extraction buffer. Cell lysates from each sample are analyzed by SDS-PAGE. Membranes are incubated with phospho-MEK S221， phospho-ERK1/2 and MEK1 primary antibodies and immunoreactive proteins are analyzed by SuperSignal West Pico Chemiluminescent Substrate.[1-2] |
| 动物实验 | Colo205 xenografts are established by inoculating 5×106 cells resuspended in Hanks Balanced Salt Solution (HBSS) subcutaneously (s.c.) in the rear right flank of 6-8 week old female nude (nu/nu) mice. NCI-H2122 xenografts are established by inoculating 1×107 cells resuspended in Hanks Balanced Salt Solution (HBSS) plus matrigel (growth factor reduced) s.c. in the rear right flank of 6-8 week old female nu/nu mice. Both A375 and MiaPaca-2 xenografts are initiated by transplanting 1 mm3 tumor fragments from their respective passaged tumors s.c. into the flank of athymic nu/nu mice. When tumors reached appr 200 mm3， mice are randomized and treated with daily (QD) oral gavage (PO) with either vehicle [methylcellulose 0.1% tween 80 0.1% (MCT)]， GDC-0973 (at 10 mg/kg)， GDC-0623 (RG 7421) (40 mg/kg)， or G-573 (100 mg/kg). All doses of MEK inhibitors represented maximal tolerated doses (MTDs)， resulting in no more than 15-20% body weight loss. Tumor volumes are determined using digital calipers using the formula (L×W×W)/2. Tumor growth inhibition (%TGI) iscalculated as the percentage of the area under the fitted curve (AUC) for the respective dose group per day in relation to the vehicle. Animal weights are recorded twice per week and mice are removed from study if body weights dropped ≥20%. Partial responses (PRs) are defined as any tumor demonstrating a ≥ 50% decrease in tumor volume， whereas complete responses (CRs) are defined as any tumor demonstrating 100% reduction in tumor volume at any point during the study.[1-2] |
| 数据来源文献 | [1]. Hatzivassiliou G， et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 2013 Sep 12;501(7466):232-6. [2]. Takahashi RH， et al. Elucidating the Mechanisms of Formation for Two Unusual Cytochrome P450-Mediated Fused Ring Metabolites of GDC-0623， a MAPK/ERK Kinase Inhibitor. Drug Metab Dispos. 2015 Dec;43(12):1929-1933. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验|998894|gb|S78179.1|S78179 Oryctolagus cuniculus type XII... 32 0.037 gi|31072033|gb|AC122153.4| Oryctolagus cuniculus clone LB1-... 28 0.58 gi|1496|emb|X52496.1|OCCAATP Rabbit mRNA for calcium ATPase 28 0.58 gi|1468|emb|X02814.1|OCATPDR Rabbit mRNA
2F+DwTquooTcizAj6Sh40arj1e+iWJ2ispgsbT801bWi9OaaVDQ0u7N9Rf22Q7je3ypEkT/aXtAx/4gHh20RbetchuWXizve3YY/3L0LGHHqt8Cva+97zf/vEfvyYb4imWXpTxLz8m4rvgjodswc3X26Xnn2o3LbjZPv/Fv5GGuGa33/ZzO2n2HD17NAEWeUXwmQh44uy32U+uutL+69e+6jjedfsddvSxx3m8xNNFQ67wipqQKHyESZ35
/eYtFCYbhXr1G2Dp0qWYMmUKnJycIDQQenp6ci9KCA+iX0cSWoSQ4fDCAfb2T8iG5C1+/fKCuhAs1FURGBhEWovQiJjROw8MDKT7Md+LXjem10q0u6oqafujRdiTDBk6VHqINbiTJ87uXbtw4fwFLJg3H3NmzYYeHeu0aNkCI0aOTDatiBgnT548MWFL/mvKGtAtUpYeyd8198gEkkogbX9CJHV13D6FCQThy9mNuChs2F5vxtj+/7qGuu
技术资料暂无技术资料 索取技术资料
